Table 2.

Genetic background of AML patients and expression of OX40, OX40L.

Marker	Characteristics	N	Mutated/positive (mean + /− SD)	N	Unmutated/negative (mean + /− SD)	p value
OX40 SFI	t(15;17)	6	3.4 (4.1)	63	3.6 (5.2)	0.639
	inv(16)	4	2.2 (1.9)	63	3.7 (5.3)	0.525
	FLT3-ITD	28	5.0 (5.8)	36	2.8 (4.7)	0.025
	FLT3-TKD	5	1.7 (0.4)	59	3.9 (5.4)	0.950
	NPM1	24	5.8 (7.6)	40	2.4 (2.5)	0.131
	CEBPA	6	1.7 (0.6)	51	3.5 (4.7)	0.876
	MLL-AF9	2	1.0 (0.2)	59	3.4 (4.4)	0.096
	IDH 2	6	2.8 (2.9)	25	2.2 (2.4)	0.484
OX40%	t(15;17)	6	26.3 (33.2)	63	18.7 (25.1)	0.297
	inv(16)	4	13.6 (22.9)	63	20.3 (26.2)	0.443
	FLT3-ITD	28	28.7 (28.2)	36	13.1 (23.4)	0.020
	FLT3-TKD	5	5.4 (7.5)	59	26.6 (27.1)	0.220
	NPM1	24	27.6 (30.2)	40	14.5 (22.9)	0.149
	CEBPA	6	7.1 (9.0)	51	19.3 (26.4)	0.507
	MLL-AF9	2	2.1 (1.9)	59	19.0 (25.2)	0.331
	IDH 2	6	17.9 (22.1)	25	14.2 (25.0)	0.881
OX40L SFI	t(15;17)	6	3.5 (2.8)	63	3.0 (5.7)	0.025
	inv(16)	4	2.2 (1.1)	63	3.1 (5.8)	0.220
	FLT3-ITD	28	3.3 (6.6)	36	2.9 (5.0)	0.516
	FLT3-TKD	5	3.7 (5.1)	59	3.1 (5.8)	0.770
	NPM1	24	3.0 (6.4)	40	3.2 (5.2)	0.224
	CEBPA	6	1.3 (0.6)	51	3.5 (6.3)	0.061
	MLL-AF9	2	1.1 (0.2)	59	3.2 (5.9)	0.268
	IDH 2	6	6.2 (12.3)	25	4.1 (7.4)	0.530
OX40L %	t(15;17)	6	40.6 (22.7)	63	13.5 (2.2)	0.004
	inv(16)	4	19.0 (16.6)	63	14.8 (23.5)	0.126
	FLT3-ITD	28	15.1 (23.5)	36	15.5 (23.6)	0.977
	FLT3-TKD	5	21.6 (26.3)	59	14.9 (23.3)	0.956
	NPM1	24	14.2 (22.8)	40	16.1 (24.0)	0.588
	CEBPA	6	5.1 (10.2)	51	17.5 (24.7)	0.007
	MLL-AF9	2	2.19 (3.09)	59	15.4 (23.4)	0.245
	IDH 2	6	22.6 (33.5)	25	23.9 (29.5)	0.962

Significant values are in bold.